CooperVision has announced it has completed enrolment of its global MiSight 1 day post-approval clinical studies in the US and China.

CooperVision said this milestone in real-world evidence generation for paediatric myopia control, together with the seven-year clinical trial of ActivControl Technology, represents the longest clinical evidence programme undertaken for contact lens-based myopia control intervention in children.  

The post-approval studies comprise both randomised controlled efficacy trials and large-scale safety registries and include 100-plus clinical sites and more than 3,000 children. Data will supplement the MiSight 1 day clinical studies, which have been widely published and cited in the ophthalmology and optometry communities, the company said.  

“Completing enrolment is a crucial step, allowing us to start analysing data that will further illustrate how MiSight 1 day performs in real-world settings over multiple years,” said Dr Kathryn Richdale, director of post-market clinical affairs, CooperVision. “The findings will further strengthen the existing evidence supporting MiSight 1 day, helping eyecare professionals continue to make informed myopia management decisions and reinforcing long‑term confidence for families.” 

Participants in the multi-year studies represent populations across the US and China, providing insights applicable to children worldwide, CooperVision said. Final data are expected on a rolling basis between 2027 and 2030.